GlassScriptPhysician profile
Melissa A Moran
NPI 1427574839
$2,051.49
in general payments reported to CMS, 2019-2025
14 companies · $911 in 2025
The $911 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.69 · 2022: $380 · 2023: $239 · 2024: $470 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $507.24 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $281.81 | 2023-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $262.05 | 2021-2025 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.41 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $204.44 | 2022-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $155.79 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $128.44 | 2022-2025 | Ozempic, Rybelsus |
| Sequel Med Tech, LLC | $85.04 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $77.00 | 2025 | Yorvipath |
| Abbvie INC. | $29.90 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.34 | 2023 | Recorlev |
| Vapotherm INC | $20.62 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.05 | 2022 | |
| Insulet Corporation | $15.36 | 2023 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.